Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ADAG
stocks logo

ADAG

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast ADAG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADAG is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast ADAG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADAG is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.970
sliders
Low
7.00
Averages
8.00
High
9.00
Current: 1.970
sliders
Low
7.00
Averages
8.00
High
9.00
Guggenheim
initiated
$9
2025-11-24
Reason
Guggenheim
Price Target
$9
2025-11-24
initiated
Reason
As previously reported, Guggenheim initiated coverage of Adagene with a Buy rating and $9 price target. The company's lead product candidate muzastotug is currently in Phase 2 for patients with late-line microsatellite stable colorectal cancer without liver metastases, notes the analyst. The company has reported "compelling" Phase 1 data for muzastotug plus pembrolizumab that exceed current standard of care benchmarks in third-line and later CRC, according to the analyst, who calls this "an area of significant unmet need."
Guggenheim
initiated
$9
2025-11-24
Reason
Guggenheim
Price Target
$9
2025-11-24
initiated
Reason
Guggenheim initiated coverage of Adagene with a Buy rating and $9 price target.
LifeSci Capital
Outperform
initiated
$8
2025-11-14
Reason
LifeSci Capital
Price Target
$8
2025-11-14
initiated
Outperform
Reason
LifeSci Capital initiated coverage of Adagene with an Outperform rating and $8 price target.
Lucid Capital
NULL
to
Buy
initiated
$9
2025-09-18
Reason
Lucid Capital
Price Target
$9
2025-09-18
initiated
NULL
to
Buy
Reason
Lucid Capital initiated coverage of Adagene with a Buy rating and $9 price target. Adagene is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based cancer immunotherapies, the analyst tells investors in a research note. The firm estimates peak sales of $1.2B by 2039 for the company's lead asset muzastotug in metastatic colorectal cancer patients with no liver metastases. Lucid sees "significant" upside in the shares if the data continue to support a potential best-in-indication profile.
H.C. Wainwright
Arthur He
Buy
downgrade
$8 -> $7
2025-08-15
Reason
H.C. Wainwright
Arthur He
Price Target
$8 -> $7
2025-08-15
downgrade
Buy
Reason
H.C. Wainwright analyst Arthur He lowered the firm's price target on Adagene to $7 from $8 and keeps a Buy rating on the shares. The firm updated the company's model to reflect delayed launches of ADG126.
Leerink
Outperform
initiated
$7
2025-08-06
Reason
Leerink
Price Target
$7
2025-08-06
initiated
Outperform
Reason
Leerink initiated coverage of Adagene with an Outperform rating and $7 price target. The firm's positive view of the company and stock is grounded in enthusiasm for the company's lead program, muzastotug, which is a conditionally masked CTLA-4 antagonist. As emphasis on biotech in China increases, Adagene is well positioned to benefit from increased investment in the region, Leerink adds.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Adagene Inc (ADAG.O) is -2.26, compared to its 5-year average forward P/E of -3.29. For a more detailed relative valuation and DCF analysis to assess Adagene Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.29
Current PE
-2.26
Overvalued PE
-0.26
Undervalued PE
-6.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.41
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.81
Undervalued EV/EBITDA
-4.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
16.23
Current PS
0.00
Overvalued PS
42.77
Undervalued PS
-10.31
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ADAG News & Events

Events Timeline

(ET)
2025-11-13
07:25:14
Adagene Signs Licensing Deal with Third Arc Bio
select
2025-10-31 (ET)
2025-10-31
16:21:14
Adagene submits filing to offer 10.625 million ordinary shares or 8.5 million ADSs for shareholders.
select
2025-10-31
07:03:28
Adagene announces dosing of first patient in Phase 2 trial of muzastotug and KEYTRUDA
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-24Benzinga
Guggenheim Begins Coverage of Adagene with a Buy Rating and Sets Price Target at $9

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

[object Object]
Preview
9.0
10-31Newsfilter
Adagene Reports First Patient Treated in Randomized Dose Optimization Group of Phase 2 Trial for Muzastotug (ADG126) Combined with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

  • Phase 2 Clinical Trial Initiation: Adagene Inc. has commenced a Phase 2 clinical trial for muzastotug in combination with KEYTRUDA for patients with microsatellite stable colorectal cancer, with the first patient dosed in October 2025 and trial completion expected by early 2027.

  • Trial Design and Objectives: The trial will randomize patients to receive either 10 mg/kg or 20 mg/kg of muzastotug, focusing on overall response rate (ORR) as the primary endpoint, while secondary endpoints include duration of response, progression-free survival, and overall survival.

  • Previous Trial Results: In a prior Phase 1b/2 trial, muzastotug demonstrated promising results, with a 29% ORR in the 20 mg/kg cohort and favorable median overall survival rates compared to existing treatments.

  • Company Overview: Adagene is a biotechnology company specializing in antibody-based cancer immunotherapies, utilizing advanced technologies like SAFEbody to enhance safety and efficacy in targeting tumors while minimizing off-target effects.

[object Object]
Preview
4.0
09-19NASDAQ.COM
LUCID CAPITAL MARKETS Begins Coverage of Adagene Inc. - Depositary Receipt (ADAG) with a Buy Rating

  • Analyst Coverage Initiation: LUCID CAPITAL MARKETS has initiated coverage of Adagene Inc. (NasdaqGM:ADAG) with a Buy recommendation, projecting a 377.44% upside based on an average one-year price target of $9.84/share.

  • Fund Sentiment and Ownership: There has been a 15% increase in the number of funds reporting positions in Adagene, although total shares owned by institutions decreased by 20.15% over the last three months.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Adagene Inc (ADAG) stock price today?

The current price of ADAG is 1.97 USD — it has decreased -4.37 % in the last trading day.

arrow icon

What is Adagene Inc (ADAG)'s business?

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

arrow icon

What is the price predicton of ADAG Stock?

Wall Street analysts forecast ADAG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADAG is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Adagene Inc (ADAG)'s revenue for the last quarter?

Adagene Inc revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Adagene Inc (ADAG)'s earnings per share (EPS) for the last quarter?

Adagene Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Adagene Inc (ADAG)'s fundamentals?

The market is revising No Change the revenue expectations for Adagene Inc. (ADAG) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -10.45%.
arrow icon

How many employees does Adagene Inc (ADAG). have?

Adagene Inc (ADAG) has 138 emplpoyees as of December 05 2025.

arrow icon

What is Adagene Inc (ADAG) market cap?

Today ADAG has the market capitalization of 92.85M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free